38 completed, 3 recruiting, 2 active not recruiting, 2 terminated. 48 Phase 2, 9 Phase 3, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 48 | Completed 38, Recruiting 3, Active not recruiting 2, Terminated 2, Unknown 2, Withdrawn 1 |
| Phase 3 | 9 | Completed 9 |
| Phase 1 | 6 | Completed 3, Active not recruiting 2, Terminated 1 |
Follow Eisai Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of E6742 in Participants With Systemic Lupus Erythematosus E6742, Placebo - Systemic Lupus Erythematosus | Phase 2 | Recruiting | Eisai Co., Ltd. | 256 | 2026-03-31 | 2026-08-21 |
| A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia Disorder Lemborexant, PBO - Sleep Initiation and Maintenance Disorders | Phase 2 | Completed | Eisai Co., Ltd. | 65 | 2022-11-30 | 2025-07-03 |
| Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant Laboratory Biomarker Analysis, Lenvatinib - Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | Terminated | Emory University | 3 | 2022-04-19 | 2026-04-24 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Participants E6742, Placebo - Lupus Erythematosus, Systemic | Phase 1 / Phase 2 | Completed | Eisai Co., Ltd. | 26 | 2022-04-14 | 2023-09-29 |
| Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor Lenvatinib + Letrozole, Fulvestrant - Breast Cancer | Phase 2 | Recruiting | National University Hospital, Singapore | 120 | 2021-12-27 | 2025-07-25 |
| NCCH2006/MK010 Trial (FORTUNE Trial) E7090 - Advanced or Recurrent Solid Tumors, FGFR Gene Alterations | Phase 2 | Recruiting | National Cancer Center, Japan | 75 | 2021-06-15 | 2025-10-03 |
| A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion E7090 - Cholangiocarcinoma | Phase 2 | Completed | Eisai Co., Ltd. | 63 | 2020-01-22 | 2026-03-02 |
| A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor E7389-LF, Nivolumab - Solid Neoplasms | Phase 1 / Phase 2 | Active not recruiting | Eisai Co., Ltd. | 125 | 2019-09-05 | 2026-10-13 |
| A Study of Intravenous Perampanel in Japanese Participants With Epilepsy Perampanel - Epilepsy, Seizures | Phase 2 | Completed | Eisai Co., Ltd. | 21 | 2018-11-27 | 2021-01-05 |
| Lenvatinib and Pembrolizumab Simultaneous Combination Study Lenvatinib, Pembrolizumab - Advanced Gastric Cancer | Phase 2 | Completed | National Cancer Center Hospital East | 29 | 2018-10-03 | 2025-04-16 |
| Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling Lenvatinib - Cancer | Phase 2 | Withdrawn | Teresa Helsten, MD | 2018-07-01 | 2018-08-02 | |
| Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation Tazemetostat - Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | Phase 2 | Completed | Eisai Co., Ltd. | 20 | 2018-04-09 | 2022-12-16 |
| Phase II Study of Single Agent Lenvatinib lenvatinib - Breast Cancer | Phase 2 | Unknown | National University Hospital, Singapore | 30 | 2017-03-28 | 2017-06-16 |
| A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Biologics E6011, Placebo - Rheumatoid Arthritis | Phase 2 | Completed | Eisai Co., Ltd. | 66 | 2016-11-26 | 2021-08-23 |
| A Dose Response Study of E6011 in Participants With Rheumatoid Arthritis Inadequately Responding to Methotrexate E6011, Placebo - Rheumatoid Arthritis | Phase 2 | Completed | Eisai Co., Ltd. | 273 | 2016-10-20 | 2021-06-21 |
| Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma E7777 - Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma | Phase 2 | Completed | Eisai Co., Ltd. | 45 | 2016-03-28 | 2021-07-15 |
| Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy Lenvatinib - Biliary Tract Cancer | Phase 2 | Completed | Eisai Co., Ltd. | 29 | 2015-10-23 | 2020-12-23 |
| Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer Lenvatinib + Letrozole - Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | National University Hospital, Singapore | 40 | 2015-10-02 | 2025-09-25 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Diseases and Thrombocytopenia avatrombopag, Placebo - Thrombocytopenia Associated With Chronic Liver Disease | Phase 2 | Completed | Eisai Co., Ltd. | 39 | 2014-07-01 | 2019-02-28 |
| A Study of E6011 in Japanese Subjects With Rheumatoid Arthritis E6011 - Arthritis, Rheumatoid | Phase 1 / Phase 2 | Completed | Eisai Co., Ltd. | 53 | 2014-05-26 | 2020-08-13 |
Showing 20 of 48. Sign in to see all of them.
Epilepsy (5) · Arthritis, Rheumatoid (4) · Breast Neoplasms (4) · Seizures (4) · Acrocephalosyndactylia (3) · Neoplasms (3) · Amyotrophic Lateral Sclerosis (2) · Carcinoma, Hepatocellular (2) · Crohn Disease (2) · Dementia (2) · Duodenal Ulcer (2) · Lewy Body Disease (2) · Lupus Erythematosus, Systemic (2) · Muscular Atrophy (2) · Sleep Initiation and Maintenance Disorders (2)
lenvatinib (9) · Rabeprazole (5) · perampanel (5) · Adalimumab (4) · quetmolimab (3) · Donepezil (2) · E 5555 (2) · Letrozole (2) · eribulin (2) · mecobalamin (2) · E7777 fusion protein (1) · Eszopiclone (1) · Fulvestrant (1) · N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide (1) · Nivolumab (1)
Japan (38) · Singapore (3) · South Korea (3) · China (2) · United States (2) · Bolivia (1) · Germany (1) · Latvia (1) · Taiwan (1)
Kazunori Saeki (3) · Soo Chin Lee (3) · Kazuko Kobayashi (2) · Masaru Takeuchi (2) · Nobuyuki Sugisaki (2) · Tatsuo Watanabe (2) · Atsushi Kamijo (1) · Ching Wan Chan (1) · Ern Yu Tan (1) · Faustino Torrico, PhD (1) · Hidetaka Hiramatsu (1) · Hiroshi Obaishi (1) · Isabela Ribeiro, MD (1) · Itaru Arimoto (1)
PMID 35305920, PMID 22325170, PMID 22108775, PMID 23063301, PMID 23957383, PMID 24874893, PMID 25982504, PMID 27704266, PMID 28299283, PMID 28681650, PMID 29352704, PMID 30509941, PMID 30636701, PMID 30638399, PMID 32589866, PMID 33038062, PMID 33198671, PMID 35134259, PMID 35945547, PMID 36409773, PMID 37059702, PMID 38295160, PMID 39179948, PMID 39289029, PMID 39516370, PMID 41475066
2015 (1), P30CA138292 (1)